{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:10:44Z","timestamp":1772118644300,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment\u2010na\u00efve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real\u2010life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real\u2010life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty\u2010one patients were enrolled (62% had advanced stage). iPET2 was positive in 89 patients (14%) including 8.7% and 17% early and advanced stage patients, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.003). Among iPET 2 positive cases treatment was immediately modified in 19 cases; in 14 cases treatment was modified after an additional positive iPET4. Overall 56 iPET2 positive patients never received intensified therapies. Most frequently used intensified therapy was autologous stem cell transplantation followed by BEACOPP. After a median follow\u2010up of 72\u00a0months, the 5\u2010year progression\u2010free survival (PFS) was 82% with iPET2 positive patients showing a worse PFS compared with iPET2 negative cases: 31% versus 85%. Focusing on advanced stage patients with a positive iPET2, the 5\u2010year PFS was 59% for patients shifted to intensified therapy at any time point versus 61% for patients who never received intensified therapy. Our study confirmed the higher curability of na\u00efve cHL patients in a real\u2010world setting, and the prognostic role of iPET2 in this setting. A poor adherence to response\u2010adapted strategy which however did not translate into a difference in patient outcomes.\n                  <\/jats:p>","DOI":"10.1002\/hon.3273","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:29:54Z","timestamp":1714030194000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-2246","authenticated-orcid":false,"given":"Vittorio Ruggero","family":"Zilioli","sequence":"first","affiliation":[{"name":"Division of Hematology ASST Grande Ospedale Metropolitano Niguarda  Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese &amp; University of Siena  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya De","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia e T.M.O. AORN \"S.G. Moscati\"  Avellino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pezzullo","sequence":"additional","affiliation":[{"name":"U.O.C. di Ematologia con Trapianto di Midollo Osseo A.U.O. \"San Giovanni di Dio e Ruggi D'Aragona\"  Salerno Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[{"name":"Ospedale di Circolo e Fondazione Macchi  Varese Italy"},{"name":"Hematology Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico  Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Rivellini","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia e T.M.O. AORN \"S.G. Moscati\"  Avellino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Muzi","sequence":"additional","affiliation":[{"name":"Division of Hematology ASST Grande Ospedale Metropolitano Niguarda  Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbieri","family":"Emiliano","sequence":"additional","affiliation":[{"name":"Doctorate School of Clinical and Experimental Medicine University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Linfomi Clinical Trial Office  Modena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Unit Arcispedale S. Maria Nuova Azienda Unit\u00e0 Sanitaria Locale \u2010 IRCCS University of Modena and Reggio Emilia  Reggio Emilia Italy"},{"name":"Chimomo Department University of Modena and Reggio Emilia  Reggio Emilia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210095"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153745"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102018.1.200"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.11.6525"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103218"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1510093"},{"key":"e_1_2_10_8_1","article-title":"Long\u2010term follow\u2010up of the response\u2010adjusted therapy for advanced hodgkin lymphoma trial","author":"Luminari S","year":"2023","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010010\u20101490\u20105"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(11)61940\u20105"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000005"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu189"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.2543"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3298"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0021"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3117"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0699"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"e_1_2_10_21_1","article-title":"Comparison of first\u2010line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz N","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_22_1","article-title":"Interim PET\u2010results for prognosis in adults with Hodgkin Lymphoma: a systematic review and meta\u2010analysis of prognostic factor studies","volume":"1","author":"Aldin A","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00811"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.015"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.012"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061760"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283694"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01777"},{"key":"e_1_2_10_30_1","article-title":"Patterns of PET\u2010positive residual tissue at interim restaging and risk of treatment failure in advanced\u2010stage Hodgkin's Lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group","author":"Ferdinandus J","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00315"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007400"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_4"}],"updated-by":[{"DOI":"10.1002\/hon.3291","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000}}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:12:02Z","timestamp":1719583922000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/hon.3273"],"URL":"https:\/\/doi.org\/10.1002\/hon.3273","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3273\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3273\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3273\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3273\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"2024-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3273"}}